Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Retained Earnings: 2016-2024

Historic Retained Earnings for Akebia Therapeutics (AKBA) over the last 9 years, with Dec 2024 value amounting to -$1.7 billion.

  • Akebia Therapeutics' Retained Earnings fell 0.96% to -$1.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.7 billion, marking a year-over-year decrease of 0.96%. This contributed to the annual value of -$1.7 billion for FY2024, which is 4.31% down from last year.
  • As of FY2024, Akebia Therapeutics' Retained Earnings stood at -$1.7 billion, which was down 4.31% from -$1.6 billion recorded in FY2023.
  • In the past 5 years, Akebia Therapeutics' Retained Earnings ranged from a high of -$1.2 billion in FY2020 and a low of -$1.7 billion during FY2024.
  • Moreover, its 3-year median value for Retained Earnings was -$1.6 billion (2023), whereas its average is -$1.6 billion.
  • As far as peak fluctuations go, Akebia Therapeutics' Retained Earnings plummeted by 48.29% in 2020, and later rose by 3.33% in 2023.
  • Over the past 5 years, Akebia Therapeutics' Retained Earnings (MRY) stood at -$1.2 billion in 2020, then fell by 24.23% to -$1.5 billion in 2021, then fell by 6.44% to -$1.6 billion in 2022, then dropped by 3.33% to -$1.6 billion in 2023, then fell by 4.31% to -$1.7 billion in 2024.
  • Its Retained Earnings stands at -$1.7 billion for FY2024, versus -$1.6 billion for FY2023 and -$1.6 billion for FY2022.